January 16, 2024
Mad Hedge Biotech and Healthcare Letter January 16, 2024 Fiat Lux Featured Trade: (PHARMA GIANTS HUNTING FOR THE NEXT BIG THING) (IMCR), (SNDX), (BPMC), (MRK), (JNJ), (HARP), (AMAM), (MDGL), (VKTX)
This author has not written his bio yet.
But we are proud to say that april@madhedgefundtrader.com contributed 3185 entries already.
Mad Hedge Biotech and Healthcare Letter January 16, 2024 Fiat Lux Featured Trade: (PHARMA GIANTS HUNTING FOR THE NEXT BIG THING) (IMCR), (SNDX), (BPMC), (MRK), (JNJ), (HARP), (AMAM), (MDGL), (VKTX)
Alright, let's dive back into the biotech pool – and no, it's not the kind where you just dip your toes. We're talking about a full-blown belly flop into the deep end of the stock market. Since October 2023, biotech stocks have been playing a game of limbo, asking themselves, "How low can you go?"
When John identifies a strategic exit point, he will send you an alert with specific trade information as to what security to sell, when to sell it, and at what price. Most often, it will be to TAKE PROFITS, but, on rare occasions, it will be to exercise a STOP LOSS at a predetermined price to adhere to strict risk management discipline.
When John identifies a strategic exit point, he will send you an alert with specific trade information on what security to sell, when to sell it, and at what price. Most often, it will be to TAKE PROFITS, but, on rare occasions, it will be to exercise a STOP LOSS at a predetermined price to adhere to strict risk management discipline.
Global Market Comments January 16, 2024 Fiat Lux Featured Trade: (MARKET OUTLOOK FOR THE WEEK AHEAD, or WHAT WILL KILL THIS MARKET) (MSFT), (BA), (AMZN), (DAL), (V), (PANW), (CCJ), (TLT), (NVDA), (META), (TSLA), (GOOGL)
What if Goldilocks decided to hang around for a while? I’ve always been in favor of a long-term relationship. It could be weeks. It could be months. Certainly, the widely predicted New Year selloff has failed to materialize. Failure to fall after the first week of 2024 has delivered a rally almost as ferocious as
Come join me for lunch at the Mad Hedge Fund Trader’s Global Strategy Luncheon, which I will be conducting in St. Augustine, Florida on Wednesday, January 22, 2025. The cost of the luncheon will be $257. An excellent meal will be followed by a wide-ranging discussion and an extended question and answer period. I’ll
Mad Hedge Technology Letter January 12, 2024 Fiat Lux Featured Trade: (FINANCE TURNS TO AI) (C), (AI)
Tech is at it again and I mean artificial intelligence doing the dirty jobs for senior executives. Citigroup (C) CEO Jane Fraser is doing the extreme by slashing a big portion of the staff and a reason to feel very comfortable about this is the upcoming implementation of generative AI into the company. The New
(SUMMARY OF JOHN’S JANUARY 10, 2024, WEBINAR) January 12, 2024 Hello everyone. Title: Exhaustion Performance: January 2024 - +3.43% MTD 2024 YTD - +3.43% Since inception - +680.03% Average annualized return - +52.08% for 15 years Positions: NVDA 2/$450-$460 call spread NVDA 2/$460-$470 call spread MSFT 2/$330 - $340 call spread
Legal Disclaimer
There is a very high degree of risk involved in trading. Past results are not indicative of future returns. MadHedgeFundTrader.com and all individuals affiliated with this site assume no responsibilities for your trading and investment results. The indicators, strategies, columns, articles and all other features are for educational purposes only and should not be construed as investment advice. Information for futures trading observations are obtained from sources believed to be reliable, but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. Your use of the trading observations is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. You must assess the risk of any trade with your broker and make your own independent decisions regarding any securities mentioned herein. Affiliates of MadHedgeFundTrader.com may have a position or effect transactions in the securities described herein (or options thereon) and/or otherwise employ trading strategies that may be consistent or inconsistent with the provided strategies.
